Kisqali Granted Breakthrough Therapy Status to Treat Breast Cancer in Premenopausal Women

Kisqali Granted Breakthrough Therapy Status to Treat Breast Cancer in Premenopausal Women
The U.S. Food and Drug Administration (FDA) has granted Kisqali (ribociclib) Breakthrough Therapy designation for the treatment of premenopausal women with HR-positive, HER2-negative advanced breast cancer who have not received prior endocrine treatment, according to Novartis. The designation, designed to expedite the development and review of treatments for serious or life-threatening conditions, was granted to Kisqali in combination

Knowledge is power when living with breast cancer.

Get access to the web’s leading Breast Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *